uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran: The RE-LY Trial
Show others and affiliations
2012 (English)In: Stroke, ISSN 0039-2499, E-ISSN 1524-4628, Vol. 43, no 6, 1511-1517 p.Article in journal (Refereed) Published
Abstract [en]

Background and Purpose-Intracranial hemorrhage is the most devastating complication of anticoagulation. Outcomes associated with different sites of intracranial bleeding occurring with warfarin versus dabigatran have not been defined.

Methods-Analysis of 18 113 participants with atrial fibrillation in the Randomized Evaluation of Long-term anticoagulant therapY (RE-LY) trial assigned to adjusted-dose warfarin (target international normalized ratio, 2-3) or dabigatran (150 mg or 110 mg, both twice daily).

Results-During a mean of 2.0 years of follow-up, 154 intracranial hemorrhages occurred in 153 participants: 46% intracerebral (49% mortality), 45% subdural (24% mortality), and 8% subarachnoid (31% mortality). The rates of intracranial hemorrhage were 0.76%, 0.31%, and 0.23% per year among those assigned to warfarin, dabigatran 150 mg, and dabigatran 110 mg, respectively (P < 0.001 for either dabigatran dose versus warfarin). Fewer fatal intracranial hemorrhages occurred among those assigned dabigatran 150 mg and 110 mg (n = 13 and n = 11, respectively) versus warfarin (n = 32; P < 0.01 for both). Fewer traumatic intracranial hemorrhages occurred among those assigned to dabigatran (11 patients with each dose) compared with warfarin (24 patients; P < 0.05 for both dabigatran doses versus warfarin). Independent predictors of intracranial hemorrhage were assignment to warfarin (relative risk, 2.9; P < 0.001), aspirin use (relative risk, 1.6; P = 0.01), age (relative risk, 1.1 per year; P < 0.001), and previous stroke/transient ischemic attack (relative risk, 1.8; P = 0.001).

Conclusions-The clinical spectrum of intracranial hemorrhage was similar for patients given warfarin and dabigatran. Absolute rates at all sites and both fatal and traumatic intracranial hemorrhages were lower with dabigatran than with warfarin. Concomitant aspirin use was the most important modifiable independent risk factor for intracranial hemorrhage.

Place, publisher, year, edition, pages
2012. Vol. 43, no 6, 1511-1517 p.
Keyword [en]
atrial fibrillation, intracranial hemorrhage, intracerebral hemorrhage, warfarin, anticoagulation, subdural hematoma, dabigatran
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-176822DOI: 10.1161/STROKEAHA.112.650614ISI: 000304523800018OAI: oai:DiVA.org:uu-176822DiVA: diva2:537720
Available from: 2012-06-27 Created: 2012-06-26 Last updated: 2012-06-27Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Wallentin, Lars
By organisation
UCR-Uppsala Clinical Research Center
In the same journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 193 hits
ReferencesLink to record
Permanent link

Direct link